Health·Implant Files

Biocell textured breast implants could soon be pulled from the market: Health Canada

Sales of Biocell textured breast implants, which had been flagged for safety issues in a joint CBC News, Toronto Star and Radio-Canada investigation could soon be suspended, Health Canada says.

Department previously warned women with implants to see a doctor if they notice any changes to their breasts

Biocell textured breast implants, made by Allergan, have come under growing scrutiny from some doctors who say they are seeing many of their patients return with debilitating pain. (Nicolas Amaya/CBC)

Sales of Biocell textured breast implants, which had been flagged for safety issues in a joint CBC News, Toronto Star and Radio-Canada investigation could soon be suspended, Health Canada says.

As of Thursday, Health Canada said it's been notified of 28 confirmed Canadian cases of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). It is a serious but rare type of non-Hodgkin lymphoma that affects the immune system and may develop many months or years after a breast implant procedure. It is not a cancer of the breast tissue.

Of the 28 cases, 24 involved Allergan's Biocell breast implant. 

Health Canada said it continues to review all scientific and clinical evidence on textured breast implants. 

"This includes any new evidence provided by Allergan in the next 15 calendar days. If a satisfactory response is not received by then, it is Health Canada's intention that the Biocell medical device licences will be suspended. This means that the product would no longer be permitted to be sold in Canada," the regulator said in a release on Thursday.

Health Canada previously warned women with implants to see a doctor if they notice any changes to their breasts including pain, sudden swelling or a lump. The department is also asking health-care professionals to report details of any cases of BIA-ALCL.

BIA-ALCL is also associated with autoimmune-like symptoms including cognitive issues, fatigue and muscle pain.

The U.S. Food and Drug Administration (FDA) was the first health authority in the world to identify a link between breast implants and BIA-ALCL back in 2011.

Officials from the FDA, along with Health Canada and European regulators, have attended public hearings focused on the use and safety of breast implants. 

Health Canada had previously said there was no need to reopen its safety review of breast implants in a response to the joint investigation by CBC News, Radio-Canada and the Star in collaboration with the Washington-based International Consortium of Investigative Journalists.

The series found that deaths and serious injuries potentially tied to breast implants and other medical devices are underreported in many countries, including Canada. Many patients told CBC they suffered serious medical problems as a result of their implants and were dismissed by health professionals.

Comments

To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.